BNIP3 and osteosarcoma: By analyzing the expression profiles and corresponding clinical data for 396 normal bone tissues from the Genotype-Tissue Expression (GTEx) database and 88 osteosarcoma samples from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) database, we constructed a risk assessment model based on FKBP11 and BNIP3 expression that can classify osteosarcoma patients into high and low risk groups and accurately predict the prognosis of patients, thus guiding the clinical treatment of osteosarcoma patients.